WASHINGTON (AP) — An analysis by U.S. regulators says Johnson &amp; Johnson's single-dose vaccine protects against COVID-19. 

The report Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. 

On Friday, a panel of experts to the Food and Drug Administration will debate if the evidence is strong enough to recommend the long-anticipated shot. The FDA is expected to make a final decision within days. 

If the FDA clears the J&amp;J shot for U.S. use, it won’t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week.

<figure>
 <img src="https://media.eaglewebservices.com/public/2020/10/1602590971875.png" alt="Vaccine photo courtesy Johnson &amp; Johnson" />
 <figcaption>Vaccine photo courtesy Johnson &amp; Johnson</figcaption>
 </figure>WASHINGTON (AP) — An analysis by U.S. regulators says Johnson &amp; Johnson's single-dose vaccine protects against COVID-19. The report Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. On Friday, a panel of experts to the Food and Drug Administration will debate if the evidence is strong enough to recommend the long-anticipated shot. The FDA is expected to make a final decision within days. If the FDA clears the J&amp;J shot for U.S. use, it won’t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week.

FDA says J&J 1-dose shot prevents COVID; final decision soon